EPHA2 and neoplasm: In cellular assays, when a chimeric protein consistingof ephrinA1and the Fc region of an antibody, ephrinA1-Fc, engages with the EphA2LBD, it causes receptor dimerization, followed by clustering and internalizationthat results in the degradation of the receptor via a lysosomal pathway.32 Therefore, because ephrinA1-Fc could in principlerevert pro-oncogenic EphA2 into a tumor suppressor, the design ofpotent and effective ephrinA1-Fc mimetics holds great potential forthe development of novel anti-metastatic therapeutics.